The porcine epidemic diarrhea vaccines market size has grown strongly in recent years. It will grow from $1.8 billion in 2025 to $1.94 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to recurring outbreaks of porcine epidemic diarrhea, high mortality rates in neonatal piglets, economic losses in the swine industry, limited effectiveness of non-vaccine disease control measures, increased reliance on veterinary-led disease prevention.
The porcine epidemic diarrhea vaccines market size is expected to see strong growth in the next few years. It will grow to $2.5 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growth of intensive pig farming practices, rising global demand for pork products, increasing awareness of herd immunity benefits, expansion of organized hog production farms, supportive government animal health initiatives. Major trends in the forecast period include increasing adoption of preventive vaccination in swine health management, growing preference for live vaccines in endemic regions, rising focus on early immunization of piglets, expansion of vaccination programs in commercial hog farms, greater emphasis on biosecurity and disease control protocols.
The growth of pig farming is expected to drive the expansion of the porcine epidemic diarrhea vaccine market in the coming years. Pig farming entails raising domestic pigs for meat production, breeding, rearing, managing animals from birth to market weight, and producing and marketing pork products. The increase in pig farming is fueled by rising global demand for pork, improvements in breeding and herd management practices, technological advancements in swine production systems, and the growth of commercial pork markets. Porcine epidemic diarrhea (PED) vaccines are essential in pig farming, helping prevent and control disease outbreaks, with administration typically occurring during the sow’s gestation period to provide passive immunity to newborn piglets. For example, in April 2024, the U.S. Department of Agriculture, a US-based government agency, projected U.S. pork production to reach 12.7 million metric tons, indicating increased swine output and supporting the ongoing growth of the pig farming industry. Consequently, the rise in pig farming is contributing to the expansion of the porcine epidemic diarrhea vaccine market.
Major companies operating in the Porcine Epidemic Diarrhea (PED) vaccines market are concentrating on creating innovative solutions such as next-generation inactivated and recombinant vaccines to boost immunity and offer broader protection against emerging PEDV strains. Next-generation inactivated and recombinant vaccines are advanced vaccines that utilize either killed viruses or engineered viral proteins to elicit strong, targeted immunity while enhancing safety and defense against evolving disease strains. For example, in August 2024, Zoetis Inc., a US-based animal health company, received a grant for Porcine Epidemic Diarrhea Virus (PEDV) vaccine research and was also granted a conditional license by the U.S. Department of Agriculture (USDA) for a vaccine to combat PEDV in pigs. These initiatives reinforce Zoetis’s position in developing advanced swine health solutions by supporting continued research, improving vaccine efficacy, and expanding protection against emerging PEDV strains.
In November 2024, Phibro Animal Health Corporation, a US-based health company, completed the acquisition of Zoetis Inc. for an undisclosed sum. The acquisition is intended to expand Phibro’s product range in medicated feed additives and water-soluble products for cattle, swine, and poultry, enhancing its capacity to support animal health and nutrition globally. It also aims to boost Phibro’s profitability, grow its revenue base, and provide capital for future investments in the animal health sector. Zoetis Inc. is a pharmaceutical manufacturing company that focuses on producing porcine epidemic diarrhea vaccines.
Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, MSD Animal Health, Elanco Animal Health, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc., Tecnovax, Komipharm International Co. Ltd., Bioveta a.s., HIPRA, CZ Vaccines.
Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2025. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the porcine epidemic diarrhea vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the porcine epidemic diarrhea vaccines market by increasing the cost of imported vaccine raw materials, biological components, and cold-chain logistics equipment. These effects are most visible in live and inactivated vaccines supplied across major swine-producing regions such as Asia-Pacific and North America. Higher input costs have influenced vaccine pricing for hog production farms and veterinary hospitals. However, tariffs have also encouraged local vaccine manufacturing and strengthened regional self-sufficiency in animal health solutions.
The porcine epidemic diarrhea vaccines market research report is one of a series of new reports that provides porcine epidemic diarrhea vaccines market statistics, including porcine epidemic diarrhea vaccines industry global market size, regional shares, competitors with a porcine epidemic diarrhea vaccines market share, detailed porcine epidemic diarrhea vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the porcine epidemic diarrhea vaccines industry. This porcine epidemic diarrhea vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Porcine epidemic diarrhea vaccines are biological preparations designed to induce immunity against the porcine epidemic diarrhea virus, which leads to severe gastrointestinal illness in pigs. These vaccines play a crucial role in preventing and managing porcine epidemic diarrhea, supporting the health and productivity of pig herds and the economic stability of the swine industry.
The primary products of porcine epidemic diarrhea vaccines include live vaccines and inactivated vaccines. Live vaccines are biological formulations that contain attenuated or weakened versions of the porcine epidemic diarrhea virus (PEDV). Their applications encompass piglets and adult pigs and are utilized by various end-users, including veterinary clinics and hog production farms.
The porcine epidemic diarrhea vaccines market consists of sales of ingelvac PEDV, barricade, PED vax, PEDV shield, and enterisol ileitis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The porcine epidemic diarrhea vaccines market size is expected to see strong growth in the next few years. It will grow to $2.5 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growth of intensive pig farming practices, rising global demand for pork products, increasing awareness of herd immunity benefits, expansion of organized hog production farms, supportive government animal health initiatives. Major trends in the forecast period include increasing adoption of preventive vaccination in swine health management, growing preference for live vaccines in endemic regions, rising focus on early immunization of piglets, expansion of vaccination programs in commercial hog farms, greater emphasis on biosecurity and disease control protocols.
The growth of pig farming is expected to drive the expansion of the porcine epidemic diarrhea vaccine market in the coming years. Pig farming entails raising domestic pigs for meat production, breeding, rearing, managing animals from birth to market weight, and producing and marketing pork products. The increase in pig farming is fueled by rising global demand for pork, improvements in breeding and herd management practices, technological advancements in swine production systems, and the growth of commercial pork markets. Porcine epidemic diarrhea (PED) vaccines are essential in pig farming, helping prevent and control disease outbreaks, with administration typically occurring during the sow’s gestation period to provide passive immunity to newborn piglets. For example, in April 2024, the U.S. Department of Agriculture, a US-based government agency, projected U.S. pork production to reach 12.7 million metric tons, indicating increased swine output and supporting the ongoing growth of the pig farming industry. Consequently, the rise in pig farming is contributing to the expansion of the porcine epidemic diarrhea vaccine market.
Major companies operating in the Porcine Epidemic Diarrhea (PED) vaccines market are concentrating on creating innovative solutions such as next-generation inactivated and recombinant vaccines to boost immunity and offer broader protection against emerging PEDV strains. Next-generation inactivated and recombinant vaccines are advanced vaccines that utilize either killed viruses or engineered viral proteins to elicit strong, targeted immunity while enhancing safety and defense against evolving disease strains. For example, in August 2024, Zoetis Inc., a US-based animal health company, received a grant for Porcine Epidemic Diarrhea Virus (PEDV) vaccine research and was also granted a conditional license by the U.S. Department of Agriculture (USDA) for a vaccine to combat PEDV in pigs. These initiatives reinforce Zoetis’s position in developing advanced swine health solutions by supporting continued research, improving vaccine efficacy, and expanding protection against emerging PEDV strains.
In November 2024, Phibro Animal Health Corporation, a US-based health company, completed the acquisition of Zoetis Inc. for an undisclosed sum. The acquisition is intended to expand Phibro’s product range in medicated feed additives and water-soluble products for cattle, swine, and poultry, enhancing its capacity to support animal health and nutrition globally. It also aims to boost Phibro’s profitability, grow its revenue base, and provide capital for future investments in the animal health sector. Zoetis Inc. is a pharmaceutical manufacturing company that focuses on producing porcine epidemic diarrhea vaccines.
Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, MSD Animal Health, Elanco Animal Health, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc., Tecnovax, Komipharm International Co. Ltd., Bioveta a.s., HIPRA, CZ Vaccines.
Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2025. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the porcine epidemic diarrhea vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the porcine epidemic diarrhea vaccines market by increasing the cost of imported vaccine raw materials, biological components, and cold-chain logistics equipment. These effects are most visible in live and inactivated vaccines supplied across major swine-producing regions such as Asia-Pacific and North America. Higher input costs have influenced vaccine pricing for hog production farms and veterinary hospitals. However, tariffs have also encouraged local vaccine manufacturing and strengthened regional self-sufficiency in animal health solutions.
The porcine epidemic diarrhea vaccines market research report is one of a series of new reports that provides porcine epidemic diarrhea vaccines market statistics, including porcine epidemic diarrhea vaccines industry global market size, regional shares, competitors with a porcine epidemic diarrhea vaccines market share, detailed porcine epidemic diarrhea vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the porcine epidemic diarrhea vaccines industry. This porcine epidemic diarrhea vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Porcine epidemic diarrhea vaccines are biological preparations designed to induce immunity against the porcine epidemic diarrhea virus, which leads to severe gastrointestinal illness in pigs. These vaccines play a crucial role in preventing and managing porcine epidemic diarrhea, supporting the health and productivity of pig herds and the economic stability of the swine industry.
The primary products of porcine epidemic diarrhea vaccines include live vaccines and inactivated vaccines. Live vaccines are biological formulations that contain attenuated or weakened versions of the porcine epidemic diarrhea virus (PEDV). Their applications encompass piglets and adult pigs and are utilized by various end-users, including veterinary clinics and hog production farms.
The porcine epidemic diarrhea vaccines market consists of sales of ingelvac PEDV, barricade, PED vax, PEDV shield, and enterisol ileitis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Porcine Epidemic Diarrhea Vaccines Market Characteristics
3. Porcine Epidemic Diarrhea Vaccines Market Supply Chain Analysis
4. Global Porcine Epidemic Diarrhea Vaccines Market Trends and Strategies
5. Porcine Epidemic Diarrhea Vaccines Market Analysis of End Use Industries
7. Global Porcine Epidemic Diarrhea Vaccines Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Porcine Epidemic Diarrhea Vaccines Total Addressable Market (TAM) Analysis for the Market
9. Porcine Epidemic Diarrhea Vaccines Market Segmentation
10. Porcine Epidemic Diarrhea Vaccines Market Regional and Country Analysis
11. Asia-Pacific Porcine Epidemic Diarrhea Vaccines Market
12. China Porcine Epidemic Diarrhea Vaccines Market
13. India Porcine Epidemic Diarrhea Vaccines Market
14. Japan Porcine Epidemic Diarrhea Vaccines Market
15. Australia Porcine Epidemic Diarrhea Vaccines Market
16. Indonesia Porcine Epidemic Diarrhea Vaccines Market
17. South Korea Porcine Epidemic Diarrhea Vaccines Market
18. Taiwan Porcine Epidemic Diarrhea Vaccines Market
19. South East Asia Porcine Epidemic Diarrhea Vaccines Market
20. Western Europe Porcine Epidemic Diarrhea Vaccines Market
21. UK Porcine Epidemic Diarrhea Vaccines Market
22. Germany Porcine Epidemic Diarrhea Vaccines Market
23. France Porcine Epidemic Diarrhea Vaccines Market
24. Italy Porcine Epidemic Diarrhea Vaccines Market
25. Spain Porcine Epidemic Diarrhea Vaccines Market
26. Eastern Europe Porcine Epidemic Diarrhea Vaccines Market
27. Russia Porcine Epidemic Diarrhea Vaccines Market
28. North America Porcine Epidemic Diarrhea Vaccines Market
29. USA Porcine Epidemic Diarrhea Vaccines Market
30. Canada Porcine Epidemic Diarrhea Vaccines Market
31. South America Porcine Epidemic Diarrhea Vaccines Market
32. Brazil Porcine Epidemic Diarrhea Vaccines Market
33. Middle East Porcine Epidemic Diarrhea Vaccines Market
34. Africa Porcine Epidemic Diarrhea Vaccines Market
36. Porcine Epidemic Diarrhea Vaccines Market Competitive Landscape and Company Profiles
37. Porcine Epidemic Diarrhea Vaccines Market Other Major and Innovative Companies
40. Porcine Epidemic Diarrhea Vaccines Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Porcine Epidemic Diarrhea Vaccines Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses porcine epidemic diarrhea vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for porcine epidemic diarrhea vaccines? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The porcine epidemic diarrhea vaccines market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Live Vaccines; Killed Vaccines2) By Application: Piglets; Adults Pigs
3) By End-User: Veterinary Hospitals; Hog Production Farms
Subsegments:
1) By Live Vaccines: Oral Live Vaccines; Injectable Live Vaccines2) By Killed Vaccines: Inactivated Injectable Vaccines; Inactivated Oral Vaccines
Companies Mentioned: Zoetis Inc.; Merck Animal Health; MSD Animal Health; Elanco Animal Health; Boehringer Ingelheim Animal Health; Ceva Santé Animale; Phibro Animal Health Corporation; IDT Biologika GmbH; Vaxxinova; Qilu Animal Health Products Factory Co. Ltd.; Green Cross Veterinary Products Co. Ltd.; Nisseiken Co. Ltd.; Ourofino Saúde Animal; Medgene Labs; Harrisvaccines Inc.; Tecnovax; Komipharm International Co. Ltd.; Bioveta a.s.; HIPRA; CZ Vaccines
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Porcine Epidemic Diarrhea Vaccines market report include:- Zoetis Inc.
- Merck Animal Health
- MSD Animal Health
- Elanco Animal Health
- Boehringer Ingelheim Animal Health
- Ceva Santé Animale
- Phibro Animal Health Corporation
- IDT Biologika GmbH
- Vaxxinova
- Qilu Animal Health Products Factory Co. Ltd.
- Green Cross Veterinary Products Co. Ltd.
- Nisseiken Co. Ltd.
- Ourofino Saúde Animal
- Medgene Labs
- Harrisvaccines Inc.
- Tecnovax
- Komipharm International Co. Ltd.
- Bioveta a.s.
- HIPRA
- CZ Vaccines
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.94 Billion |
| Forecasted Market Value ( USD | $ 2.5 Billion |
| Compound Annual Growth Rate | 6.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
